Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
   
Ask the Experts About

HIV Drug ResistanceHIV Drug Resistance
           
Rollover images to visit our other forums!
  
  • Email Email
  • Glossary Glossary


Phenosense assay shows Zerit on border - Higher Dosage?
Feb 23, 2002

Greetings Dr. Little,

I have a client who recently had a PhenoSense GT assay and showed that Zerit had a fold change of 1.8, just barely over the 1.7 RS cutoff. He had read somewhere that an off-label, higher dose of Zerit can be tolerated and further may be more useful in this circumstance. He is unwilling, at this time, to go on a PI regimen. Can you help? (He also shows resistance to all of the NNRTI's.)

Best Regards,

Jason Gray Topeka AIDS Project

Response from Dr. Little

I do not think that there is currently sufficient data to support the use of higher dose d4T in patients with probable drug resistance. So - if you have phenotypic resistance, I think you are left with new drugs - or continued use of a suboptimal drug - but probably not useless drug. I would be very concerned about the toxicity of an increased dosage of d4T as well.


Previous
Driven mutations
Next
New meds for resistant virus

  
  • Email Email
  • Glossary Glossary


 
 
Advertisement




Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement